oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Bergemalm, Daniel
Publications (10 of 18) Show all publications
Eriksson, C., Bergemalm, D., Vigren, L., Nilsson, L., Visuri, I., Hjortswang, H., . . . Halfvarson, J. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. Paper presented at 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. Journal of Crohn's & Colitis, 12(Suppl. 1), S409-S410
Open this publication in new window or tab >>Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG
Show others...
2018 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S409-S410Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-66750 (URN)000427318901372 ()
Conference
13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018
Note

Funding Agency:

MSD

Available from: 2018-04-26 Created: 2018-04-26 Last updated: 2018-08-31Bibliographically approved
Eriksson, C., Rundquist, S., Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., . . . Halfvarson, J. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). Journal of Crohn's & Colitis, 12(Suppl. 1), S494-S495
Open this publication in new window or tab >>Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD)
Show others...
2018 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S494-S495Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-66751 (URN)000427318902141 ()
Available from: 2018-04-26 Created: 2018-04-26 Last updated: 2018-08-30Bibliographically approved
Eriksson, C., Rundquist, S., Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., . . . Halfvarson, J. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). Journal of Crohn's & Colitis, 12(Suppl. 1), S382-S383
Open this publication in new window or tab >>Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
Show others...
2018 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S382-S383Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-66753 (URN)000427318901324 ()
Note

Funding Agency:

Takeda

Available from: 2018-04-26 Created: 2018-04-26 Last updated: 2018-08-30Bibliographically approved
Vatn, S., Karlsson, M. C., Carstens, A., Detlie, T. E., Ricanek, P., Bergemalm, D., . . . Vatn, M. H. (2018). Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation. Journal of Crohn's & Colitis, 12(Suppl. 1), S555-S555
Open this publication in new window or tab >>Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation
Show others...
2018 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S555-S555Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-66758 (URN)000427318902249 ()
Available from: 2018-04-26 Created: 2018-04-26 Last updated: 2018-09-12Bibliographically approved
Vatn, S., Karlsson, M. C., Carstens, A., Detlie, T. E., Ricanek, P., Lindquist, C. M., . . . Vatn, M. H. (2018). Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation. Journal of Crohn's & Colitis, 12(Suppl. 1), S557-S557
Open this publication in new window or tab >>Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation
Show others...
2018 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S557-S557Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-66757 (URN)000427318902253 ()
Available from: 2018-04-26 Created: 2018-04-26 Last updated: 2018-09-12Bibliographically approved
Zammit, S. C., Ellul, P., Girardin, G., Valpiani, D., Nielsen, K. R., Olsen, J., . . . Burisch, J. (2018). Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. European Journal of Gastroenterology and Hepathology, 30(11), 1297-1303
Open this publication in new window or tab >>Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study
Show others...
2018 (English)In: European Journal of Gastroenterology and Hepathology, ISSN 0954-691X, E-ISSN 1473-5687, Vol. 30, no 11, p. 1297-1303Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Serum vitamin D level is commonly low in patients with inflammatory bowel disease (IBD). Although there is a growing body of evidence that links low vitamin D level to certain aspects of IBD such as disease activity and quality of life, data on its prevalence and how it varies across disease phenotype, smoking status and treatment groups are still missing.

MATERIALS AND METHODS: Patients diagnosed with IBD between 2010 and 2011 were recruited. Demographic data and serum vitamin D levels were collected. Variance of vitamin D level was then assessed across different treatment groups, disease phenotype, disease activity and quality of life scores.

RESULTS: A total of 238 (55.9% male) patients were included. Overall, 79% of the patients had either insufficient or deficient levels of vitamin D at diagnosis. Patients needing corticosteroid treatment at 1 year had significantly lower vitamin D levels at diagnosis (median 36.0 nmol/l) (P=0.035). Harvey-Bradshaw Index (P=0.0001) and Simple Clinical Colitis Activity Index scores (P=0.0001) were significantly lower in patients with higher vitamin D level. Serum vitamin D level correlated significantly with SIBQ score (P=0.0001) and with multiple components of SF12. Smokers at diagnosis had the lowest vitamin D levels (vitamin D: 34 nmol/l; P=0.053).

CONCLUSION: This study demonstrates the high prevalence of low vitamin D levels in treatment-naive European IBD populations. Furthermore, it demonstrates the presence of low vitamin D levels in patients with IBD who smoke.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2018
Keywords
disease activity, inflammatory bowel disease, quality of life, vitamin D
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-68564 (URN)10.1097/MEG.0000000000001238 (DOI)000446527500006 ()30134383 (PubMedID)2-s2.0-85054753889 (Scopus ID)
Available from: 2018-08-23 Created: 2018-08-23 Last updated: 2018-10-22Bibliographically approved
Bergemalm, D., Kruse, R., Sapnara, M., Halfvarson, J. & Hultgren Hörnquist, E. (2017). Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD. PLoS ONE, 12(3), Article ID e0174275.
Open this publication in new window or tab >>Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD
Show others...
2017 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 12, no 3, article id e0174275Article in journal (Refereed) Published
Abstract [en]

Background: The identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms.

Methods: Fecal samples were collected at onset of inflammation in Galphai2(-/-) mice, a well-described spontaneous model of chronic colitis, and from healthy littermates. The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were then validated in a new cohort of mice.

Results: As a potential top marker of disease, peptidase D was found at a higher ratio in Galphai24mouse feces relative to controls (fold change 27; p = 0.019). Other proteins found to be enriched in Gai2(-/-) mice were mainly pancreatic proteases, and proteins from plasma and blood cells. A tendency of increased calprotectin, subunit S100-A8, was also observed (fold change 21; p = 0.058). Proteases are potential activators of inflammation in the gastrointestinal tract through their interaction with the proteinase-activated receptor 2 (PAR2). Accordingly, the level of PAR2 was found to be elevated in both the colon and the pancreas of Galphai24- mice at different stages of disease.

Conclusions: These findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis. The elevated levels of fecal proteases may be involved in the pathogenesis of colitis and contribute to the clinical phenotype, possibly by activation of intestinal PAR2.

Place, publisher, year, edition, pages
Public Library of Science, 2017
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-57622 (URN)10.1371/journal.pone.0174275 (DOI)000399089000082 ()28323866 (PubMedID)2-s2.0-85016065409 (Scopus ID)
Note

Funding Agencies:

Bengt lhre research foundation  

Region Örebro county  OLL-526131 

Available from: 2017-05-10 Created: 2017-05-10 Last updated: 2018-07-31Bibliographically approved
Adams, A., Kalla, R., Vatn, S., Bonfiglio, F., Nimmo, E., Kennedy, N., . . . Satsangi, J. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character. Journal of Crohn's & Colitis, 11(Suppl. 1), S108-S108
Open this publication in new window or tab >>Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character
Show others...
2017 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S108-S108Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Oxford University Press, 2017
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-57778 (URN)10.1093/ecco-jcc/jjx002.187 (DOI)000398606900189 ()28172480 (PubMedID)
Available from: 2017-05-23 Created: 2017-05-23 Last updated: 2018-07-31Bibliographically approved
Kalla, R., Adams, A. T., Vatn, S., Bonfiglio, F., Nimmo, E. R., Kennedy, N. A., . . . Satsangi, J. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character. Paper presented at Annual General Meeting of the British-Society-of-Gastroenterology (BSG), Manchester, England, June 19-22, 2017. Gut, 66(Suppl. 2), A24-A25, Article ID OC-047.
Open this publication in new window or tab >>Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character
Show others...
2017 (English)In: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 66, no Suppl. 2, p. A24-A25, article id OC-047Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2017
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-66409 (URN)10.1136/gutjnl-2017-314472.47 (DOI)000427364900041 ()
Conference
Annual General Meeting of the British-Society-of-Gastroenterology (BSG), Manchester, England, June 19-22, 2017
Available from: 2018-04-09 Created: 2018-04-09 Last updated: 2018-08-16Bibliographically approved
Eriksson, C., Marsal, J., Bergemalm, D., Vigren, L., Björk, J., Eberhardson, M., . . . Halfvarson, J. (2017). Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology, 52(6-7), 722-729
Open this publication in new window or tab >>Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
Show others...
2017 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 52, no 6-7, p. 722-729Article in journal (Refereed) Published
Abstract [en]

Objectives: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness.

Materials and methods: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted. Clinical remission was defined as Patient Harvey Bradshaw index<5 in Crohn's disease (CD) and Patient Simple Clinical Colitis Activity index<3 in ulcerative colitis (UC).

Results: Two-hundred forty-six patients (147CD, 92 UC and 7 IBD-Unclassified) were included. On study entry, 86% had failed TNF-antagonist and 48% of the CD patients had undergone1 surgical resection. After a median follow-up of 17 (IQR: 14-20) months, 142 (58%) patients remained on vedolizumab. In total, 54% of the CD- and 64% of the UC patients were in clinical remission at the end of follow-up, with the clinical activity decreasing (p<.0001 in both groups). Faecal-calprotectin decreased in CD (p<.0001) and in UC (p=.001), whereas CRP decreased in CD (p=.002) but not in UC (p=.11). Previous anti-TNF exposure (adjusted HR: 4.03; 95% CI: 0.96-16.75) and elevated CRP at baseline (adjusted HR: 2.22; 95% CI: 1.10-4.35) seemed to be associated with discontinuation because of lack of response. Female sex was associated with termination because of intolerance (adjusted HR: 2.75; 95% CI: 1.16-6.48).

Conclusion: Vedolizumab-treated patients represent a treatment-refractory group. A long-term effect can be achieved, even beyond 1 year of treatment.

Place, publisher, year, edition, pages
Taylor & Francis, 2017
Keywords
Vedolizumab, clinical practice, inflammatory bowel disease, Crohn's disease, ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-57787 (URN)10.1080/00365521.2017.1304987 (DOI)000399808100018 ()28362144 (PubMedID)2-s2.0-85018512957 (Scopus ID)
Note

Funding Agencies:

Swedish Government  OLL-549221  OLL-526131  ALFSKANE-539811 

Hedlund Foundation  

Österlund Foundation  

Available from: 2017-05-23 Created: 2017-05-23 Last updated: 2018-07-31Bibliographically approved
Organisations

Search in DiVA

Show all publications